Trial Profile

A Phase 2 clinical trial assessing AV-078 in adult and pediatric patients with Tuberous Sclerosis Complex (TSC) refractory epilepsy

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Dec 2025 According to Aeovian Pharmaceuticals media release, company announced it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase 2 proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy.
01 Apr 2024 New trial record
28 Mar 2024 According to Aeovian Pharmaceuticals media release, the company recently completed a $50 million financing, led by Hevolution. This financing will support and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com